A meta-analysis of 23 Covid-19 treatment studies demonstrated a 47 per cent improvement when favipiravir is used in early treatment of Coronavirus. Avifavir is the first drug approved for the Coronavirus treatment in Russia, and the first Favipiravir-based drug registered in the world for treatment of the Coronavirus. It was released on the market in June 2020.